{"prompt": "['A deviation from the protocol is an unintended or unanticipated departure from the', 'procedures or processes approved by the sponsor and the IRB/IEC and agreed to by', 'the investigator. A significant deviation occurs when there is nonadherence to the', 'protocol by the patient or investigator that results in a significant, additional risk to the', 'patient. Significant deviations can include nonadherence to inclusion or exclusion', 'criteria, enrollment of the patient without prior sponsor approval, or nonadherence to', 'FDA or local regulatory authority regulations or ICH GCP guidelines, and will lead to the', 'patient being withdrawn from the study (Section 5.5).', 'Protocol deviations will be documented by the clinical monitor throughout the course of', 'monitoring visits. Principal investigators will be notified in writing by the monitor of', 'deviations. The IRB/IEC should be notified of all protocol deviations in a timely manner.', 'Intra-Cellular Therapies, Inc. Confidential', '71 ITI-007-404 Protocol Amendment V 1.3 November 5, 2018']['Intra-Cellular Therapies, Inc. Confidential', '72 ITI-007-404 Protocol Amendment V 1.3 November 5, 2018']['18 LITERATURE REFERENCES', 'Barnes TR. A rating scale for drug-induced akathisia. Br J Psychiatry. 1989;154:672-6.', 'Davis RE, Vanover KE, Zhou Y, et al. ITI-007 demonstrates brain occupancy at', 'serotonin 5-HT2A and dopamine D2 receptors and serotonin transporters using positron', 'emission tomography in healthy volunteers. Psychopharmacology (Berl).', '2015;232(15):2863-72.', 'Endicott J, Nee J, Harrison W, Blumenthal R. Quality of Life Enjoyment and Satisfaction', 'Questionnaire: A new measure. Psychopharmacology Bull. 1993;29:321-326.', 'Guy W, editor. ECDEU Assessment Manual for Psychopharmacology. Rockville: U.S.', 'Department of Health Education, and Welfare; 1976. 616 p.', 'Loebel A, Cucchiaro J, Silva R, et al. Lurasidone monotherapy in the treatment of', 'Bipolar I Depression: a randomized, double-blind, placebo-controlled study. Am J', 'Psychiatry. 2014a;171(2):160-8.', 'Loebel A, Cucchiaro J, Silva R, et al. Lurasidone as adjunctive therapy with lithium or', 'valproate for the treatment of Bipolar I Depression: a randomized, double-blind,', 'placebo-controllec study. Am J Psychiatry. 2014b;171(2):169-77.', 'Montgomery SA and \u00c4sberg M. A new depression scale designed to be sensitive to', 'change. Br J Psychiatry 1979;134:382-389.', 'Posner K, Brown GK, Stanley B, et al. The Columbia-Suicide Severity Rating Scale:', 'initial validity and internal consistency findings from three multisite studies with', 'adolescents and adults. Am J Psychiatry. 2011;168(12):1266-77.', 'Sheehan DV, Lecrubier Y, Harnett-Sheehan K, Amorim P, Janavs J, Weiller E, Hergueta', 'T, Baker R, Dunbar G. The Mini International Neuropsychiatric Interview (M.I.N.I.): The', 'Development and Validation of a Structured Diagnostic Psychiatric Interview. J Clin', 'Psychiatry. 1998;59(suppl 20):22-33.', 'Simpson GM. Angus JW. A rating scale for extrapyramidal side effects. Acta Psychiat', 'Scand Suppl. 1970;212:11-9', 'Snyder GL, Vanover KE, Zhu H, et al. Functional profile of a novel modulator of', 'serotonin, dopamine, and glutamate neurotransmission. Psychopharmacology (Berl).', '2015;232(3):605-21.', 'Intra-Cellular Therapies, Inc. Confidential', '73 ITI-007-404 Protocol Amendment V 1.3 November 5, 2018']\n\n###\n\n", "completion": "END"}